OCTAGON CAPITAL ADVISORS LP
Q3 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001839435
· CRD 306424
· SEC-registered investment adviser
$579.4M Reported Value Total
OCTAGON CAPITAL ADVISORS LP reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $1,074,417,782, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $1.2B gross asset value
Hedge Fund: $975.2M · Private Equity Fund: $200.1M
Source: Form ADV filed 2026-03-20
Reported value
$579.4M
Quarter over quarter
+22.6%
Holdings
35
Top-10 concentration
77.1%
Key People
Form ADV owners & control persons
Ting (nmn) Jia
FOUNDER, PORTFOLIO MANAGER, AND LIMITED PARTNER
Justin M Hirsch
CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2022 13F record
Q3 2022 13F filing summary
| Period of report | September 30, 2022 |
|---|---|
| Filed | November 14, 2022 |
| Form | 13F-HR |
| Reported value | $579.4M |
| Positions | 35 |
| Change in reported value | +54.6% |
| New positions | 20 |
| Exited positions | 5 |
| Position turnover | 62.5% |
| Top-10 concentration | 77.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $903.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
26 | $823.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
26 | $659.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $455.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
34 | $516.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $607.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
41 | $642.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $636.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $834.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
33 | $625.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
35 | $650.9M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
40 | $718.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
35 | $695.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
32 | $642.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
35 | $579.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
20 | $374.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
24 | $462.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
28 | $513.9M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
30 | $406.1M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | APLS APELLIS PHARMACEUTICALS INC | $171.0M | 29.5% |
| 2 | RCUS ARCUS BIOSCIENCES INC | $69.8M | 12.05% |
| 3 | KDNY CHINOOK THERAPEUTICS INC | $50.2M | 8.66% |
| 4 | HZNP HORIZON THERAPEUTICS PUB L | $38.7M | 6.67% |
| 5 | GOSS GOSSAMER BIO INC | $24.5M | 4.23% |
| 6 | TNDM TANDEM DIABETES CARE INC | $22.7M | 3.92% |
| 7 | CLDX CELLDEX THERAPEUTICS INC NEW | $21.4M | 3.69% |
| 8 | XBI SPDR SER TR | $19.3M | 3.33% |
| 9 | MRTX MIRATI THERAPEUTICS INC | $15.4M | 2.66% |
| 10 | VRNA VERONA PHARMA PLC | $13.5M | 2.34% |
| 11 | VERA VERA THERAPEUTICS INC | $11.4M | 1.96% |
| 12 | HRMY HARMONY BIOSCIENCES HLDGS IN | $10.8M | 1.86% |
| 13 | ITCI INTRA-CELLULAR THERAPIES INC | $10.3M | 1.77% |
| 14 | STOK STOKE THERAPEUTICS INC | $9.8M | 1.69% |
| 15 | BBIO BRIDGEBIO PHARMA INC | $9.3M | 1.6% |
| 16 | ALPN ALPINE IMMUNE SCIENCES INC | $8.8M | 1.52% |
| 17 | ASND ASCENDIS PHARMA A/S | $8.6M | 1.49% |
| 18 | KRTX KARUNA THERAPEUTICS INC | $7.8M | 1.34% |
| 19 | ALNY ALNYLAM PHARMACEUTICALS INC | $7.5M | 1.29% |
| 20 | FATE FATE THERAPEUTICS INC | $7.4M | 1.28% |
Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.